A relaxin-based nanotherapeutic strategy for liver fibrosis

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Targeting of the peptide hormone relaxin to injured mouse liver, via a nanoparticle/gene therapy approach, switches pro-fibrotic hepatic macrophages to a restorative phenotype that orchestrate tissue repair.
Original languageEnglish
JournalNature Nanotechnology
Early online date25 Jan 2021
DOIs
Publication statusE-pub ahead of print - 25 Jan 2021

Fingerprint

Dive into the research topics of 'A relaxin-based nanotherapeutic strategy for liver fibrosis'. Together they form a unique fingerprint.

Cite this